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CYCLOSPORINE (CyA) has been shown to be effec-
tive in a variety of human autoimmune diseases. 
including psoriasis, nephrotic syndrome, type I diabetes, 
and sight-threatening uveitis. 1 Its potential side effects 
include nephrotoxicity, diabetogenicity, and neurotoxic-
ity. Several studies (see elsewhere in this symposium) 
have shown that FK 506 prevents or suppresses autoim-
mune disorders in experimental animals and that it induces 
rapid remission in severe, recalcitrant, chronic plaque-
forming psoriasis.2.3 In this paper, the metabolic effects of 
FK 506 are reported in seven patients with severe recalci-
trant chronic plaque-forming psoriasis treated at the U ni-
versity of Pittsburgh Medical Center with a median study 
follow-up time of 6 months. 
PATIENTS AND MATERIALS 
Seven patients (2M:5F; mean age 37 years; range 30 to 49 years) 
with severe. chronic plaque-forming psoriasis unresponsive to 
conventional therapy were studied. Four patients had psoriatic 
arthritis and two of these, plus one other. had methotrexate-
induced cirrhosis. The median follow-up period for analysis was 6 
months (range 4 months-I year). Patients received a starting dose 
of 0.3 mglkgld FK 506 in oral capsule form. The dose was adjusted 
according to the FK 506 plasma levels during the study period. No 
other treatment for psoriasis was administered. One patient with 
methotrexate-induced cirrhosis required furosemide diuretic ther-
apy (40 mgld) from week 5 to week 9. 
Physical findings, including blood pressure and biochemical 
indices of renal and hepatic function and other variables, including 
glucose and cholesterol, were monitored at each clinic visit. 
Trough plasma FK 506 levels were estimated by ELISA.4 
Friedman's test was used to determine whether biochemical 
parameters changed significantly over time. The Spearman corre-
lation coefficient was calculated to investigate the association 
between FK 506 plasma levels and biochemical parameters. FK 
506 plasma levels and biochemical parameters were correlated 
with time of treatment using Spearman's correlation coefficient. A 
95% confidence interval was generated for the correlation be-
tween FK 506 plasma levels and time of treatment to compare 
biochemical parameters and FK 506 plasma levels over time. 
RESULTS 
Psoriasis 
There was complete remission of the psoriasis in all seven 
cases, as reported elsewhere.2•3 
Renal Function 
All patients showed a rise in serum creatinine compared to 
pretreatment values during the course of the study. The 
median values are shown in Fig- h: The maximal median 
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Fig 1. Median serum creatinine and FK 506 plasma levels in 
seven psoriasis patients treated with systemic FK 506. Horizontal 
bars denote normal range for serum creatinine. 
levels of plasma creatinine and B UN (Fig 2) were recorded 
at 8 weeks, after which BUN levels returned to normal. 
Elevations in creatinine levels above the normal range 
were reversible and responded to dose reduction. 
Uric acid levels showed an early, transient, and minor 
increase above normal levels. There were no alterations in 
the serum K + or Mg+ + levels throughout the study period 
(data not shown). 
Glucose Homeostasis 
An elevation in plasma glucose level was evident after 4 
weeks of treatment. The median level remained near the 
upper limit of normal from week 4 to 6 months of treatment 
(Fig 3). No patients required insulin therapy. 
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Fig 2. Median serum BUN and FK 506 plasma levels in seven 
psoriasis patients treated with systemic FK 506. Horizontal bars 
denote normal range for serum BUN. 
Uver Function 
The median total bilirubin and liver enzyme (SOOT and 
som levels remained within the normal range. In two 
patients with abnormal liver-function tests at the start of 
treatment, total bilirubin and SOOT remained elevated 
during the course of the stlldy. 
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Fig 3. Median plasma glucose and FK 506 plasma levels in 
seven psoriasis patients treated with systemic FK 506. Horizontal 
bars denote normal range for plasma gl~coseK 
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Fig 4. Median serum cholesterol and FK 506 plasma levels in 
seven psoriasis patients treated with systemic FK 506. Horizontal 
bars denote normal range for serum cholesterol. 
Cholesterol 
Cholesterol levels tended to be low throughout the study 
(Fig 4) although one patient persistently showed a minor 
elevation above the normal range. 
Blood Pressure 
Blood pressure determinations remained within the normal 
range except for one patient, whose blood pressure was at 
the upper limit of normal before treatment and who exhib-
ited minor hypertension between weeks 8 and 24 of 
treatment. 
FK 506 Plasma Levels 
The median FK 506 plasma level (shown in Figs 1 through 
4) ranged from 0.5-1.4 ng/mL during the study period. This 
range of FK 506 plasma levels was effective in inducing 
and maintaining complete remission in patients unrespon-
sive to conventional therapy. 
Statistical Analyses 
No significant change with time in any of the biochemical 
parameters was found using Friedman's test. There was a 
positive but not significant correlation between FK 506 
plasma level and serum creatinine (r = 0.071), BUN (r = 
0.084), uric acid (r = 0.193), glucose (r = 0.033) blood 
pressure (systolic r = 0.778, diastolic r = 0.569), while a 
negative correlation (r = -0.6333; NS) was found with 
cholesterol levels. 
DISCUSSION 
FK 506 shares with Cy A the potential for impairment of 
renal function and carbohydrate metabolism. 5 In this study 
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METABOLIC EFFECTS OF FK 506 
of a small number of nontransplant patients. plasma levels 
of FK 506, about I ng/mL and similar to those compatible 
with organ allograft survival. were highly effective in 
clearing psoriatic skin lesions within I month of the start of 
therapy. 
Associated with this rapid clinical response. however. 
was evidence of mild renal dysfunction and minor. tran-
sient disturbance of carbohydrate metabolism expressed 
as a mild elevation in the blood glucose level. Although 
hyperlipidemia is seen in both transplant and non trans-
plant patients treated with low-dose Cy A. this investiga-
tion has shown low cholesterol levels in FK 506-treated 
patients compared with values for normal subjects. Similar 
observations concerning lipid metabolism have been made 
in FK 506-treated transplant patients. 
There was no evidence of drug-induced hypertension in 
the present study. Hypertension may occur in as many as 
50% of patients given Cy A for autoimmune disease.6 Liver 
function was normal in this study; even with low-dose 
CyA (3 mg/kg/d). disturbances in liver function. particu-
larly in bilirubin levels. have been reported in psoriasis 
patients within 4 months of the start of treatment. 7 
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These preliminary observations on a small number of 
nontransplant patients with psoriasis show that effective 
doses of FK 506 are associated with only minor metabolic 
side effects. Further studies must now include plasma drug 
level range and long-term evaluation of FK 506 therapy in 
psoriasis. 
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